Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Southern California
With
AstraZeneca
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Postmenopausal women with newly diagnosed DCIS. Women will be considered to be in menopause if they fall into one of the following groups:
* Age \> 60
* Age \> 45 with amenorrhea \> 1 year with intact uterus
* Status post bilateral oophorectomies
* FSH/estradiol levels in postmenopausal range for the institution
DCIS must have been diagnosed with a minimally invasive biopsy technique, such as a vacuum-assisted large core tool (Mammotome) or an equivalent method.
There must be available tissue from the diagnostic biopsy to perform molecular markers.
Baseline mammogram within 8 weeks of study entry.
Serum creatinine less than or equal to 2.0 mg/dl.
Total bilirubin less than or equal to 2.0 upper limit of normal (ULN), transaminases (SGOT and/or SGPT) and alkaline phosphatase may be up to 2.5 x institutional upper limit of normal (ULN), AGC greater than or equal to 1500, platelets greater than or equal to 100,000, Hemoglobin greater than or equal to 8.0 g/dl
Peripheral neuropathy grade 0-1.
No prior therapy for DCIS.
SWOG performance status of less than or equal to 1
All patients must provide informed written consent
You may not be if
Prior hormonal therapy (antiestrogens, estrogen, SERM's, progestins, or aromatase inhibitors) within 6 months of study entry.
Underlying medical, psychiatric or social conditions that would preclude patient from receiving treatment.
History of DVT or Pulmonary Embolism
Clareo Health | A Pilot Clinical Trial to Evaluate the Biological Activity of Fulvestrant in Breast Ductal Carcinoma in Situ (DCIS)
